Mesenchymal Stem Cells in a Transgenic Mouse Model of Multiple System Atrophy: Immunomodulation and Neuroprotection
Open Access
- 18 May 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (5) , e19808
Abstract
Mesenchymal stem cells (MSC) are currently strong candidates for cell-based therapies. They are well known for their differentiation potential and immunoregulatory properties and have been proven to be potentially effective in the treatment of a large variety of diseases, including neurodegenerative disorders. Currently there is no treatment that provides consistent long-term benefits for patients with multiple system atrophy (MSA), a fatal late onset α-synucleinopathy. Principally neuroprotective or regenerative strategies, including cell-based therapies, represent a powerful approach for treating MSA. In this study we investigated the efficacy of intravenously applied MSCs in terms of behavioural improvement, neuroprotection and modulation of neuroinflammation in the (PLP)-αsynuclein (αSYN) MSA model. MSCs were intravenously applied in aged (PLP)-αSYN transgenic mice. Behavioural analyses, defining fine motor coordination and balance capabilities as well as stride length analysis, were performed to measure behavioural outcome. Neuroprotection was assessed by quantifying TH neurons in the substantia nigra pars compacta (SNc). MSC treatment on neuroinflammation was analysed by cytokine measurements (IL-1α, IL-2, IL-4, IL-5, IL-6, IL-10, IL-17, GM-CSF, INFγ, MCP-1, TGF-β1, TNF-α) in brain lysates together with immunohistochemistry for T-cells and microglia. Four weeks post MSC treatment we observed neuroprotection in the SNc, as well as downregulation of cytokines involved in neuroinflammation. However, there was no behavioural improvement after MSC application. To our knowledge this is the first experimental approach of MSC treatment in a transgenic MSA mouse model. Our data suggest that intravenously infused MSCs have a potent effect on immunomodulation and neuroprotection. Our data warrant further studies to elucidate the efficacy of systemically administered MSCs in transgenic MSA models.Keywords
This publication has 58 references indexed in Scilit:
- Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's diseaseTranslational Research, 2010
- Genetic Variants of the α-Synuclein Gene SNCA Are Associated with Multiple System AtrophyPLOS ONE, 2009
- Striatal transplantation in a rodent model of multiple system atrophy: Effects on L‐Dopa responseJournal of Neuroscience Research, 2008
- Concise Review: Mesenchymal Stem/Multipotent Stromal Cells: The State of Transdifferentiation and Modes of Tissue Repair—Current ViewsStem Cells, 2007
- Pathology and genetics of multiple system atrophy: an approach to determining genetic susceptibility spectrumActa Neuropathologica, 2006
- Alterations of T-lymphocyte populations in Parkinson diseaseParkinsonism & Related Disorders, 2005
- Hyperphosphorylation and insolubility of α‐synuclein in transgenic mouse oligodendrocytesEMBO Reports, 2002
- Adult Bone Marrow Stromal Cells Differentiate into Neural Cells in VitroExperimental Neurology, 2000
- Clinical features and natural history of multiple system atrophyBrain, 1994
- Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome)Journal of the Neurological Sciences, 1989